OBJECTIVES/HYPOTHESIS: To determine the feasibility and cost effectiveness of incorporating cytomegalovirus (CMV) testing to determine the etiology of pediatric hearing loss. STUDY DESIGN: Retrospective study of children presenting with sensorineural hearing loss (SNHL) at one institution from 2008 to 2013. METHODS: Children aged 3 years or younger who presented to the senior author (A.P.) between May 2008 and September 2013 with confirmed SNHL were evaluated. These children underwent a sequential diagnostic paradigm that incorporated CMV testing if no obvious etiology could be determined from the history or physical examination. RESULTS: One hundred eleven children with SNHL were evaluated between 2008 and 2013. Eighty-three children underwent CMV testing, imaging, and a genetic evaluation. Those with confirmed or probable CMV-induced SNHL made up 30% of all children tested (n = 25), the largest group identified. CMV screening had the lowest cost compared to genetic testing or imaging for all types of hearing loss, except for those with auditory neuropathy spectrum disorder. CONCLUSION: We present the first sequential diagnostic paradigm utilizing CMV testing for children presenting with SNHL. The relatively high incidence of CMV-induced SNHL, the low cost for this assay, and the indirect benefits from early diagnosis support the role of early CMV testing for these patients. LEVEL OF EVIDENCE: 4.
OBJECTIVES/HYPOTHESIS: To determine the feasibility and cost effectiveness of incorporating cytomegalovirus (CMV) testing to determine the etiology of pediatric hearing loss. STUDY DESIGN: Retrospective study of children presenting with sensorineural hearing loss (SNHL) at one institution from 2008 to 2013. METHODS:Children aged 3 years or younger who presented to the senior author (A.P.) between May 2008 and September 2013 with confirmed SNHL were evaluated. These children underwent a sequential diagnostic paradigm that incorporated CMV testing if no obvious etiology could be determined from the history or physical examination. RESULTS: One hundred eleven children with SNHL were evaluated between 2008 and 2013. Eighty-three children underwent CMV testing, imaging, and a genetic evaluation. Those with confirmed or probable CMV-induced SNHL made up 30% of all children tested (n = 25), the largest group identified. CMV screening had the lowest cost compared to genetic testing or imaging for all types of hearing loss, except for those with auditory neuropathy spectrum disorder. CONCLUSION: We present the first sequential diagnostic paradigm utilizing CMV testing for children presenting with SNHL. The relatively high incidence of CMV-induced SNHL, the low cost for this assay, and the indirect benefits from early diagnosis support the role of early CMV testing for these patients. LEVEL OF EVIDENCE: 4.
Authors: Anna M H Korver; Richard J H Smith; Guy Van Camp; Mark R Schleiss; Maria A K Bitner-Glindzicz; Lawrence R Lustig; Shin-Ichi Usami; An N Boudewyns Journal: Nat Rev Dis Primers Date: 2017-01-12 Impact factor: 52.329
Authors: Kyle T Fletcher; Erin M Wolf Horrell; John Ayugi; Catherine Irungu; Maria Muthoka; Liza M Creel; Cathy Lester; Matthew L Bush Journal: Otol Neurotol Date: 2018-08 Impact factor: 2.311
Authors: Tatiana M Lanzieri; Winnie Chung; Marily Flores; Peggy Blum; A Chantal Caviness; Stephanie R Bialek; Scott D Grosse; Jerry A Miller; Gail Demmler-Harrison Journal: Pediatrics Date: 2017-02-16 Impact factor: 7.124
Authors: Ali Almishaal; Pranav Dinesh Mathur; Lesley Franklin; Kevin Shi; Travis Haller; Aleksandra Martinovic; Kayla Hirschmugl; Brian R Earl; Chong Zhang; Jun Yang; Michael R Deans; Matthew A Firpo; Albert H Park Journal: Int J Pediatr Otorhinolaryngol Date: 2020-08-04 Impact factor: 1.675
Authors: Ali A Almishaal; Pranav D Mathur; Elaine Hillas; Liting Chen; Anne Zhang; Jun Yang; Yong Wang; Wayne M Yokoyama; Matthew A Firpo; Albert H Park Journal: PLoS Pathog Date: 2017-08-31 Impact factor: 6.823